Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 10,349 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 10,349 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total value of C$110,630.81. Following the sale, the director directly owned 2,709,294 shares of the company’s stock, valued at C$28,962,352.86. The trade was a 0.38% decrease in their ownership of the stock.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, February 2nd, Rostislav Christov Raykov purchased 15,598 shares of Fennec Pharmaceuticals stock. The shares were bought at an average price of C$3.37 per share, with a total value of C$52,565.26.

Fennec Pharmaceuticals Price Performance

FRX remained flat at C$10.50 during trading on Friday. The company has a market cap of C$358.61 million, a P/E ratio of -40.38 and a beta of 2.97. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.02 and a 1-year high of C$13.83. The business has a fifty day simple moving average of C$10.50 and a 200-day simple moving average of C$11.41.

Wall Street Analyst Weigh In

Separately, B.Riley Securit raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Strong Buy”.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.